We have developed and validated a new and reliable gradient reversed-phase high-performance liquid chromatography (RP-HPLC) method with a diode array detector (DAD) for the simultaneous separation and determination of 23 frequently prescribed selected drugs belonging to different therapeutic groups in human urine samples. For the drugs listed below, this method of analysis for human urine was also successfully applied to determine urine concentrations of these drugs in samples from treated patients: enalapril (ENA), paracetamol (PAR), sotalol (SOT), dipyrone (DIP), vancomycin (VAN), captopril (CAP), fluconazole (FLU), cefazolin (CEF), metoprolol (MET), aspirin (ASP), ticlopidine (TIC), prednisolone (PRE), propranolol (PRO), digoxin (DIG), sildenafil (SIL), furosemide (FUR), dexamethasone (DEX), carvedilol (CAR), ketoprofen (KET), nifedipine (NIF), terbinafine (TER), acenocoumarol (ACE) and spironolactone (SPI). Separation of the analytes was achieved by RP-HPLC-DAD with a mobile phase composed of acetonitrile, methanol and 0.05% trifluoroacetic acid in water using a gradient elution program. Good linear relationships over the investigated concentration ranges were observed with values of r 2 higher than 0.998 for all of the drugs. The intra-day and inter-day precisions of this method were evaluated with RSD values less than 4.26 and 5.42%, respectively. The relative recoveries of the 23 investigated compounds ranged from 93.60 to 106.00% with RSD values less than 4.46%. An expanded uncertainty budget was constructed for all investigated drugs in human urine samples.
Introduction
The most characteristic feature of drug treatment in elderly people is polypragmasia, the simultaneous use of many drugs in the same patient. For example, older patients who have had myocardial infarction should be treated with antiplatelet drugs, β-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs, preferably statins, according to the American College of Cardiology/American Heart Association guidelines. The same patients often suffer from many other co-morbidities like hypertension, congestive heart failure and atrial fibrillation being the most common. All of them are also treated with drugs. This creates challenging situations for the doctors who must have control over pharmacokinetics, drug interactions and the frequency of side effects.
These factors create a need for laboratory diagnostic tools that can help control drug levels in patients. The ideal could be a system where the long list of the above-mentioned drug concentrations could be measured simultaneously in the most non-invasive way e.g. from urine samples. Such systems can help physicians optimize the treatment by using the lowest effective dosage, and have a chance to identify unexpected changes in drug concentrations at an early stage. Therefore, it is necessary to develop an analytical method for the simultaneous determination of selected drugs in biological fluids. Studies concerning the marking of selected drugs analyzed by us and other authors (PAR, DIP, VAN, FLU, CEF, PRE, SIL, FUR, DEX and KET) were presented in our earlier work. [1] [2] [3] Different analytical methods have been applied to the determination of the remaining drugs analyzed by us, and also by HPLC techniques. Many of the HPLC analytical methods exist for the assay of ENA, [4] [5] [6] [7] SOT, [8] [9] [10] [11] [12] [13] [14] [15] CAP, [16] [17] [18] [19] [20] [21] [22] [23] [24] MET, [25] [26] [27] [28] [29] [30] [31] 62, 63 and SPI [64] [65] [66] [67] [68] in different biological fluids and tissues. HPLC methods were applied to the simultaneous quantification of selected β-blockers (also: SOT, MET and PRO) in human fluids (plasma, serum, urine). [69] [70] [71] There is no analytical method for the simultaneous analysis of the 23 selected drugs belonging to four different groups in human urine samples in the scientific literature. It should be emphasized that the simultaneous analysis of several drugs is much more important and effective than the detection of one drug alone in urine samples. It is necessary to emphasize that this is the first elaborated and validated method that enables the simultaneous determination of 23 selected drugs in one chromatographic system in human urine samples. The authors suggested a simple method for a simultaneous and quick analysis of 23 drugs for laboratories, which did not dispose of the MS detector instead. This method could find application in following therapy of given drugs in toxicological research for the identification of drugs, which the patient was treated with besides these drugs given by a doctor, and eventually in other needs for the determination of different drugs.
Experimental

Chemicals and reagents
The following gives details concerning the purity and the sources for the drugs: ENA maleate salt (≥98% purity), (±)-SOT hydrochloride (≥98% purity), VAN hydrochloride (≥90% purity), (±)-MET (+)-tartrate salt (≥99% purity), ASP (≥99% purity), TIC hydrochloride (≥99% purity), PRE (≥99% purity), (±)-PRO hydrochloride (≥99% purity), FUR (≥98% purity), DEX (≥98% purity), (±)-KET (≥98% purity), NIF (≥98% purity) and SPI (≥97% purity) were purchased from Sigma-Aldrich (Schnelldorf, Germany). PAR (≥98% purity), CAP (≥99% purity), CEF sodium salt (≥98% purity) and DIG (≥95% purity) were obtained from Fluka BioChemika (Darmstadt, Germany). DIP monohydrate (99.8% purity) was bought from Riedel-de Haën (Seelze, Germany). The stock solution contained FLU at a concentration of 2 mg mL -1 (Diflucan ® ), and was obtained from Pfizer (Amboise, France). SIL citrate (70.7% activity) was obtained from Pfizer Pharmaceuticals (NY). (±)-CAR (≥99% purity) and TER hydrochloride (≥99% purity) were kindly provided by Toronto Research Chemicals Inc. (North York, Ontario, Canada). ACE (≥99% purity) was obtained from U. S. Pharmacopoeia (Rockville, MD, USA). HPLC-grade acetonitrile, methanol, water, trifluoroacetic acid and a buffer (boric acid/potassium chloride/sodium hydroxide, pH 9.00) were purchased from Merck (Darmstadt, Germany). All other chemicals and reagents used were of good commercial quality available and obtained from POCH S.A. (Gliwice, Poland).
Human urine was collected from healthy human volunteers of different sex and age, who had not previously taken any drug. In this work the authors also analyzed urine samples from patients treated with some studied drugs. These urine samples were either analyzed immediately, or they were stored at -18 C until being analyzed. The urine samples were generally analyzed directly in a 24 h collection. There were also researched after urine refrigeration for 2 -3 days without any essential changes in the analyte concentrations.
Equipment and instrumentation
Chromatographic experiments were performed using the Merck-Hitachi (Darmstadt, Germany) liquid chromatographic equipment consisting of a Model L-6200A Intelligent Pump with a dynamic mixing chamber, a Model L-4500A diode array detector (DAD), equipped with a Rheodyne 7161 manual sample injector (20 µL injection volume). Program and calculations were performed by an HPLC System Manager HSM D-7000, Ver. 2.1 (Merck-Hitachi). Chromatographic separation of analytes was achieved using a Merck LiChroCART ® analytical column (Purospher ® STAR RP-18 endcapped; 250 × 4 mm i.d.; 5 µm particle size; 120 Å pore size) equipped with a Merck LiChroCART ® guard column (LiChrospher ® 100 RP-18 endcapped; 4 × 4 mm i.d.; 5 µm particle size; 100 Å pore size). A centrifuge HERMLE Z 323K (Gosheim, Germany) was used on human urine samples. pH measurements were performed with the aid of an ELMETRON CP-401 (Zabrze, Poland) pH meter.
Chromatographic conditions
All experiments were performed at laboratory temperature (ca. 22 C). Effectual elution and separation of the 23 examined drugs from the chromatographic columns were carried out using a gradient elution technique. The mobile phase comprised various proportions of acetonitrile, methanol and 0.05% trifluoroacetic acid in water. The effluent from the column was monitored by a DAD in the range of 200 -450 nm. For the washing needle, methanol was used. After a run was completed, the column reequilibration time was 20 min.
Standard and working solutions
Stock standard solutions in 1 mg mL -1 concentration (as free base) of ENA, PAR, SOT, DIP, VAN, CAP, FLU, CEF, MET, ASP, TIC, PRE, PRO, DIG, SIL, FUR, DEX, CAR, KET, NIF, TER, ACE, SPI were prepared in 10 mL volumetric flasks by dissolving an appropriate amount of reference substance, weighed in a mixture of methanol/water (1/1, v/v) and kept at -18 C. The FLU stock solution was prepared by diluting a 5 mL solution of FLU (2 mg mL -1 ) in 5 mL of a mixture of water/methanol (1/1, v/v). Stock standard solutions were prepared at the beginning of the study and were stored at 4 C.
Working standard solutions containing the investigated drugs were prepared shortly before the analysis by mixing appropriate volumes of stock solutions and diluting these mixtures in water.
Sample preparation
Standard, urine samples were prepared as follows in order to be chromatographically analyzed. One milliliter of urine was placed into a clean centrifuge tube (10 mL), and then appropriate amounts of working standard solutions were added to each tube. Next, the buffer (boric acid/potassium chloride/sodium hydroxide, pH 9.00) was used for adjusting the required pH (i.e., pH 7). The solution was mixed with 1.5 mL acetonitrile and 1.5 mL methanol. After shaking for 1 min, the sample was transferred to a centrifuge tube and centrifuged for another 15 min at 6500 rpm at room temperature (ca. 22 C). Next, the sample was transferred to a volumetric flask (10 mL), and diluted to the mark with water. The obtained sample was filtered through a syringe filter (0.45 µm), and aliquots (20 µL) were subjected to RP-HPLC analysis. Reference working standard solutions of all compounds were prepared daily to check the resolution of the chromatographic system. Human urine samples from treated patients were analyzed according to the same procedure.
Calibration curves
Linearity calibration curves for the 23 analytes were assessed at six or more concentration levels, and triplicate injections were applied at each concentration. Calibration curves (y = ax + b) were constructed by plotting the peak areas (y) versus the concentrations (x) of the calibration standards. Calibration curves as peak areas versus standard concentrations were obtained with the use of a least-squares linear regression method. The concentrations of the analyzed compounds were determined by calculating the peak area and interpolation of the respective calibration curve.
Precision
The precision, expressed as a relative standard deviation (RSD), was determined by back-calculation of the concentrations from the respective calibration curves. The RSDs were determined by the following formula: RSD (%) = (SD/mean) × 100%. Known amounts of studied drug standard solutions were added to known amounts of real samples, which had already been analyzed.
Accuracy
The accuracy of the method was evaluated by calculating the difference between the peak-area ratios of spiked and original samples, then by comparing these differences with the peak areas obtained by injecting standard solutions having the same concentration as the sample spiking. The accuracy, expressed as the percent error, was measured by determining the concentration of drugs measured in each sample relative to the known amount of each drug added.
Specificity
The specificity of the new RP-HPLC-DAD method was investigated by analyzing six different batches of drug-free human urine for the exclusion of any endogenous co-eluting interferences at the peak region of each analyte.
Recovery
The recovery was determined by comparing the amount of analyte added to the sample and the amount of analyte detected during RP-HPLC-DAD analysis.
The recoveries were determined by the following formula: recovery (%) = (concentration found -concentration added) × 100%.
Results and Discussion
Development of the RP-HPLC-DAD method
We also studied the optimization of the proposed procedure, and examined the conditions which could affect the results. Reversed-phase chromatographic conditions were found to be suitable to modulate the retention of all of the selected drugs. In analytical liquid chromatography, gradient elution is widely applied to improve the separation of mixtures by varying the solvent strength during the elution process. In the present work, the optimum gradient was selected through a large number of empirical attempts. Applications of the gradient with a growing elution force allowed to separate compounds with lower polarity and to reduce analysis time. The optimized gradient effluent conditions for the analysis of 23 drugs were obtained. The gradient program of the optimum elution profile and the mobile phase flow rate are presented in Table 1 .
This gradient program was selected to achieve the maximum separation and sensitivity. The new method was tested in model samples, and afterwards in urine samples for a final target application. A satisfactory separation of all investigated analytes from biological endogenous components in human urine was obtained. Figure 1 shows typical RP-HPLC-DAD chromatograms of a combined standard solution (A), urine sample from a healthy human volunteer (B), and urine sample from a healthy human volunteer spiked with a combined standard solution (C). Drug identification in urine was performed according to the standard addition method. Absorption spectra of the examined drugs were also compared. The average retention times for ENA, PAR, SOT, DIP, VAN 
Calibration curves and linearity
By examining the calibration curves and the table, it can be observed that the relationship between the peak area and the concentration is linear within the studied concentration range. The linearity of the calibration curves for the 23 drugs was achieved for concentrations of 0.05 -45 µg mL -1 .
High correlation coefficient values (r 2 ≥ 0.9982) were achieved in relatively wide concentration ranges for all of the analytes.
The results of a regression analysis on the calibration curves are reported in Table 2 . The optimized method was validated by a standard procedure to evaluate if adequate precision, accuracy and linearity had been achieved. From the respective area counts, the concentrations of the all analyzed drugs were calculated using the detector responses. The used concentration ranges of the analyzed drugs were based on the concentration ranges expected in the urine samples. The total linearity proved the suitability of the worked-out method for quantitative measurements of all the analytes in unknown human urine samples.
Precision and accuracy
This chromatographic system was validated for both intra-day and inter-day precision. The precision was evaluated with a standard mixture solution of the drugs under the optimal conditions six times in one day for intra-day variation and three times a day on three consecutive days for the inter-day variation, expressed as the relative standard deviation (RSD). The precisions ranged from 1.35 to 5.41% RSD, which should be satisfactory to determine the drugs in a sample matrix.
The accuracy of the method was verified by means of recovery studies, adding known amounts of ENA, PAR, SOT, DIP, VAN, CAP, FLU, CEF, MET, ASP, TIC, PRE, PRO, DIG, SIL, FUR, DEX, CAR, KET, NIF, TER, ACE and SPI standard solutions to a known amount of urine, and subjecting the mixture to the usual preparation procedure (n = 6) for each concentration tested.
The method proved to be very accurate. The percent bias for all calibration samples varied from 0.60 to 6.00%. The assay method was validated with intra-day and inter-day variations of less than 4.3 and 5.5%, respectively. The method meets all common requirements for both accuracy and precision.
Analytes recoveries
The recoveries of the examined compounds from human urine were determined at different concentrations. The samples were prepared and quantified in accordance with sections previously described. The average relative recoveries for ENA, PAR, SOT, DIP, VAN 
Specificity
To evaluate the specificity of the method, 1 mL of drug-free urine was carried through the assay procedure, and the retention times of endogenous compounds in the urine were compared with those of ENA, PAR, SOT, DIP, VAN, CAP, FLU, CEF, MET, ASP, TIC, PRE, PRO, DIG, SIL, FUR, DEX, CAR, KET, NIF, TER, ACE and SPI. No interfering peaks were observed near the retention time of the analyzed drugs in six batches of human urine samples. There were some additional, unidentified peaks in the chromatograms coming from the human urine samples, but these peaks did not interfere with the analytes of interest (Fig. 1C) .
Limits of detection and quantification
The limits of detection (LOD) and the limits of quantification (LOQ) were estimated in accordance with the baseline noise method. The LOD values were established at a signal-to-noise ratio (S/N) of 3. The LOQ were established at a signal-to-noise ratio (S/N) of 10. LOD and LOQ were experimentally appointed by six injections of mixtures (ENA, PAR, SOT, DIP, VAN, CAP, FLU, CEF, MET, ASP, TIC, PRE, PRO, DIG, SIL, FUR, DEX, CAR, KET, NIF, TER, ACE and SPI) at the LOD and LOQ concentrations. The noise of the measurements was based on ten self-contained blank urine samples (urine without any added analytes, previously prepared according to the procedure described in Sample preparation). The respective values for the 23 analytes are reported in Table 2 .
Application of the method to patient urine samples
Analyzed urine samples came from hospitalized patients who were treated with drugs orally or by injection. The developed RP-HPLC-DAD analytical method was subsequently applied to determine one or more drugs from the 23 examined analytes in human urine samples. In analyzed samples, one or more drug from the 23 examined compounds were detected. The concentrations of the examined drugs in urine samples ranged as follows: 1.24 -9.51 of PAR, 1.26 -3.52 of MET, 0.87 -2.43 of DIG and 3.14 -6.81 µg mL -1 of ACE. The precision of the signs for urine samples from patients was the same as that for urine samples after adding the examined drugs. Figure 2 shows typical RP-HPLC-DAD chromatograms of a human urine sample from a treated patient (A) and a human urine sample from a treated patient spiked with a combined standard solution (B). The urine was analyzed for 24 h. The urine sample featured in Fig. 2 was from a patient cardiologically treated. The patient was treated simultaneously with MET, DIG, ACE and PAR as an antifebrile drug.
Expanded uncertainty budget
An expanded uncertainty budget was constructed for investigated drugs in human urine by the RP-HPLC-DAD method. The expanded uncertainty budget is a powerful tool for a. Limits of detection were established at a signal-to-noise ratio (S/N) of 3. b. Limits of quantification were established at a signal-to-noise ratio (S/N) of 10. optimizing the analytical method, since it allows one to see where to concentrate the effort. The aim is to produce all of the possible sources of uncertainty for the method. The influence of all sources of errors connected with the proposed analytical procedure concerning the uncertainty of the average amount of the 23 drugs in human urine is schematically presented in Fig. 3 using an Ishikawa diagram.
The value of the expanded uncertainty was calculated according to ISO GUM guidelines 72 using the formula below:
where U is the expanded uncertainty, k the coverage factor (for a confidence level of 95%, k = 2), c the average concentration of the drug, urel(V sample) the relative standard uncertainty of the sample volume, urel(results) the relative standard uncertainty associated with the reproducibility of results, urel(recovery) the relative standard uncertainty of the analyte recovery and urel(LOD) the relative standard uncertainty of LOD. The share of the calibration graph in the uncertainty budget of the analytical method is small (r 2 > 0.9981), and was disregarded. The uncertainty originating from the received results and the estimated LOD was a large proportion of the combined uncertainty. The contributions of the recovery and sample volume components that are directly related to the steps of the instrumental analysis were relatively small. Table 3 gives the magnitudes of the relative and expanded uncertainty for determining the examined drugs in human urine.
Conclusion
The determination of the RP-HPLC-DAD method for accurate measurements of 23 analyzed drug concentrations in human urine samples from patients suffering from different illnesses was elaborated. In this study we developed a simple and reliable procedure for the determination of ENA, PAR, SOT, DIP, VAN, CAP, FLU, CEF, MET, ASP, TIC, PRE, PRO, DIG, SIL, FUR, DEX, CAR, KET, NIF, TER, ACE and SPI in human urine by gradient RP-HPLC with ultraviolet detection. A RP-HPLC-DAD technique with very good precision, accuracy, linearity and recovery has been developed and validated.
Simple, fast and effective sample preparation for analysis makes it an easy decision about applying the method in a medical laboratory. Though all studied drugs do not have to be applied simultaneously, this method enables the determination of the one or several analyzed drugs in one run time in urine samples from treated patients. Practical implications of this depend on the possibility of simultaneous separation and analysis of several drugs in the same chromatography system. The good validation criteria results of the method allowed its use in the quantification of these compounds.
